

## Supplementary Information

### Physiological activation of human and mouse bitter taste receptors by bile acids

Florian Ziegler, Alexandra Steuer, Antonella Di Pizio and Maik Behrens\*

Leibniz Institute for Food Systems Biology at the Technical University of Munich, Freising, Germany.

\*Send correspondence to: Maik Behrens, Leibniz Institute for Food Systems Biology at the Technical University of Munich, Lise-Meitner Str. 34, 85354 Freising, Germany. E-mail: [m.behrens@leibniz-lsb@tum.de](mailto:m.behrens@leibniz-lsb@tum.de)

#### Supplementary Figures

**Supplementary Figure 1: Concentration-response relationships of the activation of the human TAS2R4 by bile acids**

**Supplementary Figure 2: Concentration-response relationships of the activation of the human TAS2R14 by bile acids**

**Supplementary Figure 3: Concentration-response relationships of the activation of the human TAS2R39 by bile acids**

**Supplementary Figure 4: Concentration-response relationships of the activation of the human TAS2R46 by bile acids**

**Supplementary Figure 5: Concentration-response relationships of the activation of the murine Tas2r105 by bile acids**

**Supplementary Figure 6: Concentration-response relationships of the activation of the murine Tas2r108 by bile acids**

**Supplementary Figure 7: Concentration-response relationships of the activation of the murine Tas2r117 by bile acids**

**Supplementary Figure 8: Concentration-response relationships of the activation of the murine Tas2r123 by bile acids**

**Supplementary Figure 9: Concentration-response relationships of the activation of the murine Tas2r126 by bile acids**

**Supplementary Figure 10: Concentration-response relationships of the activation of the murine Tas2r144 by bile acids**

**Supplementary Figure 11: 3D representations of the putative binding modes of bile acids in the TAS2R1 binding site obtained with MM/GBSA refinement.**

**Supplementary Figure 12: Correlation plots for all investigated ligands.**

**Supplementary Figure 13: Amino acid sequence identities of human and mouse bile acid-sensitive receptors.**

**Supplementary Figure 14: Amino acid sequence alignment of human and mouse bile acid-sensitive receptors.**


**Supplementary Figure 15: WebLogo depiction of the amino acid sequence alignment of bile acid-sensitive human and mouse bitter taste receptors.**

**Supplementary Figure 16: 3D representation of the putative tauro lithocholic acid binding mode in the TAS2R46 binding site obtained with MM/GBSA refinement.**


Supplementary Table

**Supplementary Table 1: Calculated EC<sub>50</sub>-values of human and murine bitter taste receptors activated by bile acids**

## Supplementary Figures




**Supplementary Figure 1: Concentration-response relationships of the activation of the human TAS2R4 by bile acids.** HEK293T-G $\alpha$ 16gust44 cells were transiently transfected with the human TAS2R14 (triangle, blue) and an empty vector control (circle, blue). Individual data points are depicted accordingly by black symbols. Receptor activation was measured by increasing fluorescence intensities upon  $\text{Ca}^{2+}$  - release using an automated fluorometric imaging plate reader (FLIPR<sup>TETRA</sup>). For dose-response relationships, different concentrations of the bile acids cholic acid a), glycocholic acid b), taurocholic acid c), deoxycholic acid d), tauroolithocholic acid e) and ursodeoxycholic acid f) were applied. The relative fluorescence intensities were mock subtracted and plotted against the bile acid concentration in  $\mu\text{M}$  ( $n \geq 3$  biologically independent experiments). Data are presented as the mean  $\pm$  standard deviation (STD).




**Supplementary Figure 2: Concentration-response relationships of the activation of the human TAS2R14 by bile acids.** HEK293T-G $\alpha$ 16gust44 cells were transiently transfected with the human TAS2R14 (triangle, blue) and


an empty vector control (circle, blue). Individual data points are depicted accordingly by black symbols. Receptor activation was measured by increasing fluorescence intensities upon  $\text{Ca}^{2+}$  - release using an automated fluorometric imaging plate reader (FLIPR<sup>TETRA</sup>). For dose-response relationships, different concentrations of the bile acids cholic acid a), glycocholic acid b), taurocholic acid c), tauroolithocholic acid d) and chenodeoxycholic acid e) were applied. The relative fluorescence intensities were mock subtracted and plotted against the bile acid concentration in  $\mu\text{M}$  ( $n \geq 3$  biologically independent experiments). Data are presented as the mean  $\pm$  standard deviation (STD).




**Supplementary Figure 3: Concentration-response relationships of the activation of the human TAS2R39 by bile acids.** HEK293T-G $\alpha$ 16gust44 cells were transiently transfected with the human TAS2R39 (triangle, blue) and an empty vector control (circle, blue). Individual data points are depicted accordingly by black symbols. Receptor activation was measured by increasing fluorescence intensities upon  $\text{Ca}^{2+}$  - release using an automated fluorometric imaging plate reader (FLIPR<sup>TETRA</sup>). For dose-response relationships, different concentrations of the bile acids cholic acid a), glycocholic acid b) and taurocholic acid c) were applied. The relative fluorescence intensities were mock subtracted and plotted against the bile acid concentration in  $\mu\text{M}$  ( $n \geq 3$  biologically independent experiments). Data are presented as the mean  $\pm$  standard deviation (STD).




**Supplementary Figure 4: Concentration-response relationships of the activation of the human TAS2R46 by bile acids.** HEK293T-G $\alpha$ 16gust44 cells were transiently transfected with the human TAS2R46 (triangle, blue) and an empty vector control (circle, blue). Individual data points are depicted accordingly by black symbols. Receptor activation was measured by increasing fluorescence intensities upon  $\text{Ca}^{2+}$  - release using an automated fluorometric imaging plate reader (FLIPR<sup>TETRA</sup>). For dose-response relationships, different concentrations of the bile acids glycocholic acid a), taurocholic acid b) and tauroolithocholic acid c) were applied. The relative fluorescence intensities were mock subtracted and plotted against the bile acid concentration in  $\mu\text{M}$  ( $n \geq 3$  biologically independent experiments). Data are presented as the mean  $\pm$  standard deviation (STD).




**Supplementary Figure 5: Concentration-response relationships of the activation of the murine Tas2r105 by bile acids.** HEK293T-G $\alpha$ 16gust44 cells were transiently transfected with the human Tas2r105 (triangle, blue) and an empty vector control (circle, black). Individual data points are depicted accordingly by black symbols. Receptor activation was measured by increasing fluorescence intensities upon  $\text{Ca}^{2+}$  - release using an automated fluorometric imaging plate reader (FLIPR<sup>TETRA</sup>). For dose-response relationships, different concentrations of the bile acids cholic acid a), glycocholic acid b) and deoxycholic acid c) were applied. The relative fluorescence intensities were mock subtracted and plotted against the bile acid concentration in  $\mu\text{M}$  ( $n \geq 3$  biologically independent experiments). Data are presented as the mean  $\pm$  standard deviation (STD).




**Supplementary Figure 6: Concentration-response relationships of the activation of the murine Tas2r108 by bile acids.** HEK293T-G $\alpha$ 16gust44 cells were transiently transfected with the human Tas2r108 (triangle, blue) and an empty vector control (circle, black). Individual data points are depicted accordingly by black symbols. Receptor activation was measured by increasing fluorescence intensities upon  $\text{Ca}^{2+}$  - release using an automated fluorometric imaging plate reader (FLIPR<sup>TETRA</sup>). For dose-response relationships, different concentrations of the bile acids cholic acid a), glycocholic acid b), taurocholic acid c) and deoxycholic acid d) were applied. The relative fluorescence intensities were mock subtracted and plotted against the bile acid concentration in  $\mu\text{M}$  ( $n \geq 3$  biologically independent experiments). Data are presented as the mean  $\pm$  standard deviation (STD).




**Supplementary Figure 7: Concentration-response relationships of the activation of the murine Tas2r117 by bile acids.** HEK293T-G $\alpha$ 16gust44 cells were transiently transfected with the human Tas2r117 (triangle, blue) and an empty vector control (circle, blue). Individual data points are depicted accordingly by black symbols. Receptor activation was measured by increasing fluorescence intensities upon  $\text{Ca}^{2+}$  - release using an automated fluorometric imaging plate reader (FLIPR<sup>TETRA</sup>). For dose-response relationships, different concentrations of the bile acids cholic acid a), glycocholic acid b) and taurocholic acid c) were applied. The relative fluorescence intensities were mock subtracted and plotted against the bile acid concentration in  $\mu\text{M}$  ( $n \geq 3$  biologically independent experiments). Data are presented as the mean  $\pm$  standard deviation (STD).




**Supplementary Figure 8: Concentration-response relationships of the activation of the murine Tas2r123 by bile acids.** HEK293T-G $\alpha$ 16gust44 cells were transiently transfected with the human Tas2r123 (triangle, blue) and an empty vector control (circle, blue). Individual data points are depicted accordingly by black symbols. Receptor activation was measured by increasing fluorescence intensities upon  $\text{Ca}^{2+}$  - release using an automated fluorometric imaging plate reader (FLIPR<sup>TETRA</sup>). For dose-response relationships, different concentrations of the bile acids cholic acid a), glycocholic acid b), taurocholic acid c), deoxycholic acid d) and ursodeoxycholic acid e) were applied. The relative fluorescence intensities were mock subtracted and plotted against the bile acid concentration in  $\mu\text{M}$  ( $n \geq 3$  biologically independent experiments). Data are presented as the mean  $\pm$  standard deviation (STD).




**Supplementary Figure 9: Concentration-response relationships of the activation of the murine Tas2r126 by bile acids.** HEK293T-G $\alpha$ 16gust44 cells were transiently transfected with the human Tas2r126 (triangle, blue) and an empty vector control (circle, blue). Individual data points are depicted accordingly by black symbols. Receptor activation was measured by increasing fluorescence intensities upon  $\text{Ca}^{2+}$  - release using an automated fluorometric imaging plate reader (FLIPR<sup>TETRA</sup>). For dose-response relationships, different concentrations of the bile acids cholic acid a) and glycocholic acid b) were applied. The relative fluorescence intensities were mock subtracted and plotted against the bile acid concentration in  $\mu\text{M}$  ( $n \geq 3$  biologically independent experiments). Data are presented as the mean  $\pm$  standard deviation (STD).



**Supplementary Figure 10: Concentration-response relationships of the activation of the murine Tas2r144 by bile acids.** HEK293T-G $\alpha$ 16gust44 cells were transiently transfected with the human Tas2r144 (triangle, blue) and an empty vector control (circle, blue). Individual data points are depicted accordingly by black symbols. Receptor activation was measured by increasing fluorescence intensities upon  $\text{Ca}^{2+}$  - release using an automated fluorometric imaging plate reader (FLIPR<sup>TETRA</sup>). For dose-response relationships, different concentrations of the bile acids cholic acid (a), glycocholic acid (b) and taurocholic acid (c) were applied. The relative fluorescence intensities were mock subtracted and plotted against the bile acid concentration in  $\mu\text{M}$  ( $n \geq 3$  biologically independent experiments). Data are presented as the mean  $\pm$  standard deviation (STD).



**Supplementary Figure 11:** 3D representations of the putative binding modes of a) tauroolithocholic acid, b) chenodeoxycholic acid, c) ursodeoxycholic acid, d) deoxycholic acid, e) cholic acid, f) glycocholic acid, g) taurocholic acid in the TAS2R1 binding site obtained with MM/GBSA refinement.




**Supplementary Figure 12:** Correlation plots of a) docking scores vs. activation thresholds and b) MM/GBSA scores vs. activation thresholds for all investigated ligands.



|          | TAS2R14 | Tas2r123 | TAS2R46 | Tas2r117 | Tas2r105 | Tas2r126 | TAS2R1 | TAS2R39 | Tas2r144 | TAS2R4 | Tas2r108 |
|----------|---------|----------|---------|----------|----------|----------|--------|---------|----------|--------|----------|
| TAS2R14  |         | 44,15    | 42,38   | 41,12    | 30,82    | 22,64    | 24,93  | 23,33   | 20,52    | 20,54  | 21,43    |
| Tas2r123 | 44,15   |          | 38,46   | 37,54    | 28,49    | 24,72    | 23,21  | 22,46   | 19,61    | 20,51  | 21,37    |
| TAS2R46  | 42,38   | 38,46    |         | 33,83    | 33,12    | 29,88    | 28,43  | 23,12   | 19,28    | 22,81  | 24,45    |
| Tas2r117 | 41,12   | 37,54    | 33,83   |          | 29,29    | 24,21    | 24,05  | 22,65   | 19,37    | 20,94  | 20,94    |
| Tas2r105 | 30,82   | 28,49    | 33,12   | 29,29    |          | 26,14    | 28,21  | 23,26   | 20,72    | 22,74  | 21,50    |
| Tas2r126 | 22,64   | 24,72    | 29,88   | 24,21    | 26,14    |          | 25,93  | 24,44   | 23,10    | 25,91  | 24,39    |
| TAS2R1   | 24,93   | 23,21    | 28,43   | 24,05    | 28,21    | 25,93    |        | 23,70   | 25,23    | 20,69  | 21,32    |
| TAS2R39  | 23,33   | 22,46    | 23,12   | 22,65    | 23,26    | 24,44    | 23,70  |         | 47,93    | 28,45  | 26,76    |
| Tas2r144 | 20,52   | 19,61    | 19,28   | 19,37    | 20,72    | 23,10    | 25,23  | 47,93   |          | 27,95  | 25,23    |
| TAS2R4   | 20,54   | 20,51    | 22,81   | 20,94    | 22,74    | 25,91    | 20,69  | 28,45   | 27,95    |        | 66,56    |
| Tas2r108 | 21,43   | 21,37    | 24,45   | 20,94    | 21,50    | 24,39    | 21,32  | 26,76   | 25,23    | 66,56  |          |


**Supplementary Figure 13:** Amino acid sequence identities of human and mouse bile acid-sensitive receptors. The pairwise amino acid sequence identities of the indicated bitter taste receptors in % were determined with CLC Main Workbench 22.0.2.





WebLogo 3.7.12

**Supplementary Figure 15:** WebLogo depiction of the amino acid sequence alignment (done with CLC Main Workbench 22.0.2) of bile acid-sensitive human and mouse bitter taste receptors. Positions indicated by red arrows refer to bile acid interacting positions in TAS2R1. WebLogo was created with the Web Logo 3 tool (<https://weblogo.threeplusone.com>).



**Supplementary Figure 16:** 3D representation of the putative binding mode of tauroolithocholic acid in the TAS2R46 (PDB ID: 7XP5) binding site obtained with MM/GBSA refinement (score: -70.21 kcal/mol).

### Supplementary Table

**Supplementary Table 1:** Calculated EC<sub>50</sub>-values of human and murine bitter taste receptors activated by bile acids.

|                               | TAS2R1       | TAS2R46      | Tas2r108     | Tas2r117      |
|-------------------------------|--------------|--------------|--------------|---------------|
| <b>Cholic Acid</b>            | -            | -            | -            | 20.6 ± 5.1 μM |
| <b>Chenodeoxycholic Acid</b>  | -            | -            | -            | -             |
| <b>Lithocholic Acid</b>       | 0.9 ± 0.1 μM | -            | -            | -             |
| <b>Deoxycholic Acid</b>       | 6.1 ± 0.6 μM | -            | -            | -             |
| <b>Taurocholic Acid</b>       | -            | -            | -            | 37.4 ± 7.3 μM |
| <b>Glycocholic Acid</b>       | -            | -            | -            | 16.0 ± 2.5 μM |
| <b>Tauroolithocholic Acid</b> | 1.9 ± 0.9 μM | 1.7 ± 0.2 μM | 2.3 ± 1.8 μM | -             |
| <b>Ursodeoxycholic Acid</b>   | -            | -            | -            | -             |